Results 171 to 180 of about 49,657 (223)

Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa. [PDF]

J Int AIDS Soc, 2019
Mazanderani AH, Murray TY, Sherman GG, Snyman T, George J, Avenant T, Goga AE, Pepper MS, du Plessis N.   +8 more
europepmc   +1 more source

A computational study for rational HIV-1 non-nucleoside reverse transcriptase inhibitor selection and the discovery of novel allosteric pockets for inhibitor design. [PDF]

Biosci Rep, 2018
Chiang RZ, Gan SK, Su CT.
europepmc   +1 more source

Nucleoside reverse transcriptase inhibitors as a therapeutic opportunity to counteract inflammaging and age-related diseases: New evidence from epidemiological data

Olivieri Fabiola, Giuliani Angelica, Massimiliano Bonafè   +2 more
openalex   +1 more source

Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity

, 1993
Alfred Mertens, Harald Zilch, Bernhard Koenig, Wolfgang Schaefer, Thomas S. van der Poll, Wolfgang Kampe, Hans Seidel, Ulrike Leser, Herbert Leinert   +8 more
openalex   +1 more source

Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study. [PDF]

Infect Drug Resist, 2018
Cheng CY, Tsai MS, Yang CJ, Cheng SH, Sun HY, Chang SF, Su LH, Su YC, Hung CC, Chang SY.   +9 more
europepmc   +1 more source

Synthesis and Anti-HIV Activity of New Metabolically Stable Alkenyldiarylmethane Non-Nucleoside Reverse Transcriptase Inhibitors Incorporating N-Methoxy Imidoyl Halide and 1,2,4-Oxadiazole Systems

, 2007
Takeshi Sakamoto, Matthew D. Cullen, Tracy L. Hartman, Karen Watson, Robert W. Buckheit, Christophe Pannecouque, Erik De Clercq, Mark Cushman   +7 more
openalex   +1 more source

HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo. [PDF]

Cell Transplant, 2016
Jin J, Grimmig B, Izzo J, Brown LAM, Hudson C, Smith AJ, Tan J, Bickford PC, Giunta B.   +8 more
europepmc   +1 more source

Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase

, 2008
Zachary K. Sweeney, James P. Dunn, Yu Li, Gabrielle Heilek, Pete Dunten, Todd R. Elworthy, Xiaochun Han, Seth F. Harris, Donald R. Hirschfeld, J. Heather Hogg, Walter Huber, Ann C. Kaiser, D Kertesz, Woongki Kim, Taraneh Mirzadegan, Michael G. Roepel, Yoshio Saitō, Tania M.P.C. Silva, Steven Swallow, Jahari Laurant Tracy, Armando G. Villaseñor, Harit Vora, Amy S. Zhou, Klaus Klumpp   +23 more
openalex   +1 more source

DISTINCT MECHANISMS OF HIV-1 HYPERSUSCEPTIBILITY TO NON- NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS: A DISCUSSION OF NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR INDUCED MUTATIONS V118I, H208Y, AND T215Y [PDF]

, 2008
Shauna Clark
openalex  

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.

Lancet Glob Health
Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells RJ, Naidoo K, Sosibo P, van Heerden R, Garrett N, Dorward J.   +10 more
europepmc   +1 more source